Rx for Change — Binge-Eating Disorder: Another Invented Disease Brought to You by Pharma

Taken from the May/June 2015 issue of the Womens Health Activist Newsletter.

Sadly, Adriane’s hearty appetite may indicate she has a new disease: binge-eating disorder. We learned this through a disease awareness campaign, which publicizes a disease without mentioning specific drugs. These campaigns are often used when there’s only one drug to treat a disease; the process is simplified when the company invented the disease to begin with!

Drug manufacturer Shire created “binge-eating disorder” to promote several amphetamine drugs, including Adderall (mixed amphetamine salts) and Vyvanse (lis-dexanfetamine mesylate). According to BingeEatingDisorder.com (which doesn’t mention drugs or Shire):

  • Symptoms include “regularly eating far more food than most people would in a similar time period under similar circumstances.” Check!
  • And, “Feeling that one’s eating is out of control during a binge. The feeling of not being in control can be either the inability to keep from starting to eat or the inabilty [sic] to stop eating once a binge eating episode has begun.” Check! (When they say, “the inability to keep from starting to eat…” we wonder, before a meal…when one is hungry?)
  • “To qualify as ‘regular binge eating,’ the instances must take place at least once per week for three months.” Check! (Only once a week? How about three meals a day?)
  • “The time period during which binge eating instances take place can vary by individual, but is generally considered to be less than two hours and does not have to be in one setting.” Check! (We think they mean “one sitting,” but most meals last less than two hours anyway.)

We hope no one thinks being hungrier than one’s friends is a medical condition. As Julie Holland (author of Moody Bitches, about how pharmaceutical ads target women) says, “They have ads where they show a woman surrounded by pizza and hamburgers and donuts and it says, ‘If you eat more than you want to and feel guilty afterwards, you may have this disorder.’ Which is sort of like saying, “If you’re a woman, you have this.”1

In fact, binge-eating disorder only became a disease in 2013, when the American Psychiatric Association proclaimed it to be one. The new disease was likely created to extend the patent for Vyvanse (first approved for Attention Deficit and Hyperactivity Disorder [ADHD]), since approval for a new indication – even an invented one- confers additional years of patent protection.

In 2011, Shire stated that it intended to expand Vyvanse’s use for other conditions, including schizophrenia, depression, and binge-eating.2 In 2014, Shire agreed to pay $56.5 million to settle charges it over-promoted ADHD drugs (it allegedly said Vyvanse could help prevent car accidents, divorce, arrests, and unemployment).3 The fine is nothing compared to Shire’s profits. Vyvanse is a blockbuster drug that makes over $1 billion a year, and binge-eating disorder sales are expected to add $200-$300 million annually.4

Let’s be clear: binge eating can be a symptom of anxiety, stress, or low-self esteem.  Binge eating is also part of bulimia, an eating disorder in which people binge and then purge by vomiting or using laxatives. (But “binge-eating disorder”, which is bulimia-minus-vomiting, is not a separate, real disease..) Binge eating is best and most successfully treated with therapy and support groups.5

Since binge eating can indicate a propensity for addictive behavior, treating it with an addictive drug is a bad idea. Yet, that’s just what is happening, because Vyvanse is essentially “speed.” Binge-eaters need therapy, and overweight people need diet and exercise. In any case, addicting patients to amphetamines is a bad idea.

Sure, speed causes weight loss, but the health risks aren’t worth it. Besides addiction, amphetamines like Vyvanse can cause strokes, heart attacks, death, psychotic symptoms, mania, anxiety, and insomnia.6 Since Vyvanse was approved in 2007, the FDA has received more than 130 reports linking it with suicide.7

It’s bad enough that a dangerous drug will be used to treat a widely promoted, made-up disease.It’s worse that this dangerous, addictive drug will be prescribed off-label to treat people who are overweight. Although the FDA expressly stated that Vyvanse was not approved for weight loss, clinicians are likely to prescribe it for that purpose.9 Since everyone has eaten “far more food than most people would in a similar time period under similar circumstances,” clinicians may well decide any overweight person qualifies for this bogus diagnosis and dangerous treatment.

The FDA really bolloxed its 2015 approval of Vyvanse for binge-eating disorder. It didn’t ask for outside review and even gave Vyvanse fast-track regulatory review, which should be reserved for important drugs for real diseases. Medicalizing normal human behavior or common symptoms, and renaming subsets or combinations of symptoms, are common strategies to sell drugs. The FDA needs to step up its game and protect the public from disease-mongering scams.

Editor's note: Many in the eating disorders community, patients as well as practitioners, recognize uncontrollable eating as a type of eating disorder.  The National Institutes of Health recognizes this as binge-eating disorder. In the community of people who have not experienced eating disorders, the phrase binge-eating more commonly refers to an unwise choice that is ultimately under the control of the person who binged. For more information about eating disorders, see this NIH webpage Eating Disorders: About More Than Food.

Charlea T. Massion, MD, is a practicing physician in Santa Cruz County specializing in hospice and palliative care. Charlea brought her passion for improving women’s health along with 40+ years of health care experience to the NWHN as a member of the board for 8 years. She also co-founded the American College of Women’s Health Physicians.

Adriane Fugh-Berman, MD, is a former NWHN Board Chair whose research presents a critical analysis of the marketing of prescription drugs. Adriane educates prescribers on pharmaceutical marketing practices as Director of the PharmedOUT program, and created the Health in the Public Interest program at Georgetown University School of Medicine where she trains a new generation of consumer advocates.

Read more from Charlea T. Massion and Adriane Fugh-Berman.

The continued availability of external resources is outside of the NWHN’s control. If the link you are looking for is broken, contact us at nwhn@nwhn.org to request more current citation information.


1. Kirkland A, “Feeling intense emotions doesn’t make you crazy — but that’s not what Big Pharma wants you to think,” Raw Story, April 1, 2015. Available online at:


2.  Whitman E, “Binge-Eating Disorder Drug: Vyvanse, Controversial ADHD Medication, Approved by FDA,” International Business Times, February 6, 2015. Available online at:

3.  Associated Press, “Justice Department says Shire will pay $56.5 million fine,” The Boston Globe, September 25, 2014, Available online at:


4.  Thomas K. “Shire, Maker of Binge-Eating Drug Vyvanse, First Marketed the Disease,” New York Times, February 25, 2015. Available online at http://www.nytimes.com/2015/02/25/business/shire-maker-of-binge-eating-drug-vyvanse-first-marketed-the-disease.html

5.  Krysanski VL, Ferraro FR, “Review of Controlled Psychotherapy Treatment Trials for Binge Eating Disorder,” Psychological Reports 2008; 102:339-368.

6.  Food and Drug Administration (FDA), FDA News Release: FDA expands uses of Vyvanse to treat binge-eating disorder, Rockville, MD: FDA, January 30, 2015. Available online at:  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm

7.  Whitman E, “Binge-Eating Disorder Drug: Vyvanse, Controversial ADHD Medication, Approved by FDA,” International Business Times, February 6, 2015. Available online at:



9.   Food and Drug Administration (FDA), FDA News Release: FDA expands uses of Vyvanse to treat binge-eating disorder, Rockville, MD: FDA, January 30, 2015. Available online at:  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm